Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 82,335 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. He also received 56,468 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are awards, not open-market purchases or sales.
SOPHiA GENETICS SA disclosed that Chief Financial Officer George Cardoza received new equity awards. He was granted 164,671 share options with an exercise price of $5.04 per ordinary share, expiring on April 2, 2036, and 112,936 ordinary shares as restricted stock units (RSUs). These are compensation-related grants, not open-market purchases.
The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. After these grants, Cardoza directly holds 112,936 ordinary shares and options for 164,671 shares, aligning his compensation further with long-term company performance.
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards tied to her role. She was granted share options for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units (RSUs), each representing one ordinary share upon vesting.
According to the vesting terms, 25% of the RSUs will vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, conditioned on continued service. The share options vest as to 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.
Van Well Daan reported acquisition or exercise transactions in this Form 4 filing.
SOPHiA GENETICS SA reported that Chief Legal Officer Daan Van Well received new equity compensation. He was granted options to buy 142,216 ordinary shares at $5.0400 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.
He was also granted 97,536 restricted stock units (RSUs), each representing one ordinary share. For these RSUs, 25% vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are compensation-related awards, not open-market share purchases or sales.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert had 3 Ordinary Shares sold in the open market at $4.71 per share. According to the disclosure, the sale was a “sell to cover” transaction to satisfy tax obligations from restricted stock units that vested on March 30, 2026, and was not a discretionary trade. Following this small tax-related sale, he holds 92,383 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 684 ordinary shares in an open-market transaction at a weighted average price of $4.7865 per share, within a $4.69–$4.87 range. The sale was made under a pre-established Rule 10b5-1 plan solely to cover tax obligations from restricted stock vesting. Following this tax-related sale, Van Well directly holds 261,238 ordinary shares.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 4,486 ordinary shares in an open-market transaction at a weighted average price of $4.7727 per share. The sale was executed to cover tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and was not a discretionary trade. Following this transaction, Camblong directly holds 3,302,839 ordinary shares.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 608 ordinary shares on March 19, 2026 in an open‑market transaction at a weighted average price of $4.7908 per share.
The footnotes state the sale was made to satisfy tax obligations from restricted stock units that vested on March 18, 2026 and was executed under a pre‑established Rule 10b5‑1 trading plan, meaning it was not a discretionary trade. Following the sale, Menu directly holds 173,616 shares.
SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $4.7813 per share.
The shares were sold to cover tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan, meaning the trades were not discretionary. After this transaction, Xu directly holds 537,116 Ordinary Shares.
SOPHiA GENETICS SA Chief People Officer sells small block of shares for taxes
Chief People Officer Manuela Valente sold 380 Ordinary Shares of SOPHiA GENETICS SA on March 19, 2026 in an open-market transaction at a weighted average price of $4.7851 per share, with individual sale prices ranging from $4.68 to $4.87.
The shares were sold to satisfy tax obligations from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary trades. After this transaction, Valente directly holds 152,379 Ordinary Shares.